Authors:
, , , , , , , , , , , , , , , , , and
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
Murray HW, Berman JD, Davies CR, Saravia NG, 2005. Advances in leishmaniasis. Lancet 366 :1561–1577.
-
2
Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J, 2002. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347 :1739–1746.
-
3
Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H, 2004. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 38 :1266–1272.
-
4
Davies CR, Reithinger R, Campbell-Lendrum D, Feliciangeli D, Borges R, Rodriguez N, 2000. The epidemiology and control of leishmaniasis in Andean countries. Cad Saude Publica 16 :925–950.
-
5
Soto J, Toledo J, Valda L, Balderrama M, Rea I, Parra R, Ardiles J, Soto P, Gomez A, Molleda F, Fuentelsaz C, Anders G, Sindermann H, Engel J, Berman J, 2007. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 44 :350–356.
-
6
Zentaris GmbH, 2004. Impavido Package Insert: Section 4.3. Frankfurt, Germany: Zentaris GmbH.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 1685 | 1542 | 314 |
| Full Text Views | 424 | 16 | 1 |
| PDF Downloads | 148 | 16 | 3 |
Efficacy of Miltefosine for Bolivian Cutaneous Leishmaniasis
Jaime Soto
Jaime Soto
Fundación FADER, Bogota, Colombia; Puesto de Salud, Campamento OSCAR, Palos Blancos, Bolivia; Hospital de Clínicas, La Paz, Bolivia; and AB Foundation, Rockville, Maryland
Search for other papers by Jaime Soto in
Current site
Google Scholar
PubMed
Search for other papers by Jaime Soto in
Current site
Google Scholar
PubMed
Jaime Rea
Jaime Rea
Fundación FADER, Bogota, Colombia; Puesto de Salud, Campamento OSCAR, Palos Blancos, Bolivia; Hospital de Clínicas, La Paz, Bolivia; and AB Foundation, Rockville, Maryland
Search for other papers by Jaime Rea in
Current site
Google Scholar
PubMed
Search for other papers by Jaime Rea in
Current site
Google Scholar
PubMed
Margarita Balderrama
Margarita Balderrama
Fundación FADER, Bogota, Colombia; Puesto de Salud, Campamento OSCAR, Palos Blancos, Bolivia; Hospital de Clínicas, La Paz, Bolivia; and AB Foundation, Rockville, Maryland
Search for other papers by Margarita Balderrama in
Current site
Google Scholar
PubMed
Search for other papers by Margarita Balderrama in
Current site
Google Scholar
PubMed
Julia Toledo
Julia Toledo
Fundación FADER, Bogota, Colombia; Puesto de Salud, Campamento OSCAR, Palos Blancos, Bolivia; Hospital de Clínicas, La Paz, Bolivia; and AB Foundation, Rockville, Maryland
Search for other papers by Julia Toledo in
Current site
Google Scholar
PubMed
Search for other papers by Julia Toledo in
Current site
Google Scholar
PubMed
Paula Soto
Paula Soto
Fundación FADER, Bogota, Colombia; Puesto de Salud, Campamento OSCAR, Palos Blancos, Bolivia; Hospital de Clínicas, La Paz, Bolivia; and AB Foundation, Rockville, Maryland
Search for other papers by Paula Soto in
Current site
Google Scholar
PubMed
Search for other papers by Paula Soto in
Current site
Google Scholar
PubMed
Luis Valda
Luis Valda
Fundación FADER, Bogota, Colombia; Puesto de Salud, Campamento OSCAR, Palos Blancos, Bolivia; Hospital de Clínicas, La Paz, Bolivia; and AB Foundation, Rockville, Maryland
Search for other papers by Luis Valda in
Current site
Google Scholar
PubMed
Search for other papers by Luis Valda in
Current site
Google Scholar
PubMed
Jonathan D. Berman
Jonathan D. Berman
Fundación FADER, Bogota, Colombia; Puesto de Salud, Campamento OSCAR, Palos Blancos, Bolivia; Hospital de Clínicas, La Paz, Bolivia; and AB Foundation, Rockville, Maryland
Search for other papers by Jonathan D. Berman in
Current site
Google Scholar
PubMed
Search for other papers by Jonathan D. Berman in
Current site
Google Scholar
PubMed
Oral miltefosine (2.5 mg/kg/d for 28 days) was compared with intramuscular antimony (20 mg/kg/d for 20 days) in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Palos Blancos, Bolivia. The cure rates with 6 months of follow-up were statistically similar: 36 of 41 evaluable miltefosine patients (88%) versus 15 of 16 (94%) evaluable antimony patients. However, antimony cured more rapidly, because, by 1 month after therapy, 31 of 44 miltefosine patients (70%) compared with 16 of 16 antimony patients (100%) had achieved cure. The two conclusions from this work are that oral miltefosine can be used for cutaneous disease in this part of Bolivia and that miltefosine was more effective for L. braziliensis in this region than for L. braziliensis in Guatemala. Chemotherapy needs to be evaluated in each endemic region, even if the “same” species of Leishmania causes disease in these locales.
Author Notes
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
Murray HW, Berman JD, Davies CR, Saravia NG, 2005. Advances in leishmaniasis. Lancet 366 :1561–1577.
-
2
Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J, 2002. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347 :1739–1746.
-
3
Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H, 2004. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 38 :1266–1272.
-
4
Davies CR, Reithinger R, Campbell-Lendrum D, Feliciangeli D, Borges R, Rodriguez N, 2000. The epidemiology and control of leishmaniasis in Andean countries. Cad Saude Publica 16 :925–950.
-
5
Soto J, Toledo J, Valda L, Balderrama M, Rea I, Parra R, Ardiles J, Soto P, Gomez A, Molleda F, Fuentelsaz C, Anders G, Sindermann H, Engel J, Berman J, 2007. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 44 :350–356.
-
6
Zentaris GmbH, 2004. Impavido Package Insert: Section 4.3. Frankfurt, Germany: Zentaris GmbH.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 1685 | 1542 | 314 |
| Full Text Views | 424 | 16 | 1 |
| PDF Downloads | 148 | 16 | 3 |